STAAR Surgical to Host “Vision 2026” Investor Day on September 14, 2023
- Highlighting key company initiatives and global growth opportunities.
- Positive feedback from leading refractive surgeons and EVO patients.
- None.
The “Vision 2026” Investor Day will highlight key company initiatives and projects including, several next generation product pipeline initiatives, as well as the significant global growth opportunities ahead for STAAR and its game-changing EVO ICL family of lenses for vision correction. Several leading refractive surgeons from around the world will speak to their experience with EVO ICL and share feedback from delighted EVO patients who no longer have to deal with the hassles of glasses and contact lenses and the reasons they chose EVO ICL.
Vision 2026, the in-person meeting, will be held at the Nasdaq MarketSite in
A taped replay of the event will be available at the “Investors” section of the Company’s website.
Please contact Brian Moore at bmoore@staar.com with any questions.
About STAAR Surgical
STAAR, which has been dedicated solely to ophthalmic surgery for over 40 years, designs, develops, manufactures and markets implantable lenses for the eye. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL”, which includes the EVO ICL™ product line. More than 2,000,000 ICLs have been sold to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: EVOICL.com. Headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20230907238444/en/
Investors & Media
Brian Moore
Vice President, Investor, Media Relations and Corporate Development
(626) 303-7902, Ext. 3023
bmoore@staar.com
Source: STAAR Surgical Company